You are here:

MS in the media

Published on

13 - 19 February 2016

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.

EMA guidance on PML

The European Medicines Agency has recommended updated guidance on monitoring people on Tysabri for signs of the brain infection PML.  It calls for more caution in treating people who have antibodies to the JC virus beyond two years, and more frequent MRI scans for people at a higher risk of PML.

Source: EMA

MS Trust link: Tysabri (natalizumab)

Ocrelizumab approval process in the US

The FDA, the US drug regulator, has granting "breakthrough therapy designation" to ocrelizumab as a treatment for primary progressive and relapsing MS. This means that it will be assessed more quickly when the manufacturer submits the research trial data later in the year.

Source: National MS Society (USA)

MS Trust link: Ocrelizumab

Ozanimod trial results

A phase II trial of a drug similar to fingolimod shows that it is as effective and may have fewer side effects.

Source: News Medical

MS Trust link: Drugs in development

Disease modifying drugs and progression

A poster presentation at the ACTRIMS meeting looked at records of more than 4,000 people with relapsing remitting MS to see how disease modifying drugs affected progression.  The results demonstrated the variability of disease activity but that people who had spent a shorter time on the more powerful treatments had a higher chance of reaching the outcome EDSS score.

Source: MS News Today

MS Trust link: MS Decisions - a guide to disease modifying drugs for relapsing remitting MS

Investigating the effect of other conditions on MS

As part of an ongoing project, an international group of researchers has drawn up recommendations for studying how having other health conditions (known as comorbidities) can impact on MS.  They suggest concentrating on building a better understanding of the impact of treatable comorbidities and question whether having one should exclude people from other trials.

Source: National MS Society (USA)

MS Trust link: MS research updates

Print this page